Cardiac Science v. Zoll Medical
This article was originally published in The Gray Sheet
Executive Summary
Settlement of patent infringement lawsuit includes cross-licensing of a number of patents related to automated public access defibrillators. In addition, Cardiac Science will receive an undisclosed initial licensing fee and ongoing royalties. The lawsuit involved Cardiac Science's '919 and '299 patents for electrode packaging and sensor technology and was filed March 28 in California federal court 1("The Gray Sheet" April 1, 2002, In Brief)...
You may also be interested in...
Possis Gets GPO Contract Seconds As Stock Surges In November; Index Flat
Possis Medical stock's 45% increase in November presaged new indications for the firm's AngioJet catheters and renewed group purchasing contracts
Zoll Medical AED Plus
Automated external defibrillator shipments are expected to begin this summer following 510(k) clearance, announced March 26. Zoll's first offering for the public access defibrillator market, the device incorporates Rectilinear Biphasic waveform technology and also is the first AED to feature a single electrode pad and run on off-the-shelf batteries, according to Zoll. A patent infringement suit filed by competitor Cardiac Science March 28 in California federal court relates to Cardiac Science's '919 and '299 patents for electrode packaging and sensor technology, and seeks an injunction on sales and unspecified damages. Zoll says it is "confident that the AED Plus does not infringe these patents"...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.